1238 completed, 197 unknown, 173 recruiting, 111 terminated. 353 Phase 2, 348 Phase 3, 281 Not applicable, 222 Phase 4, 213 Phase 1.
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis Patient-Reported Outcomes Dashboard With Goal Setting - Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA) | Not applicable | Not yet recruiting | Northwestern University | 160 | 2027-01-01 | 2026-10-15 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Apremilast and Adalimumab in Psoriatic Arthritis Patients Adalimumab, Apremilast - Psoriatic Arthritis, Ultrasound Assessment | Not applicable | Not yet recruiting | Tanta University | 60 | 2026-12-30 | 2026-09-08 |
| Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | Forward Therapeutics | 210 | 2026-12-01 | 2026-10-09 |
| Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic | Phase 1 | Not yet recruiting | Amgen | 114 | 2026-11-18 | 2026-11-02 |
| Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis Pentoxifylline 400 mg Oral Tablet, Placebo - Psoriasis | Not applicable | Not yet recruiting | Wasuchon Chaichan | 140 | 2026-11-01 | 2026-10-06 |
| An AI-Based Erythema Measurement System for Psoriasis Lesions No additional drugs(control Group) - Psoriasis | Not yet recruiting | Khon Kaen University | 50 | 2026-11-01 | 2026-08-05 | |
| A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis Zasocitinib - Palmoplantar Psoriasis | Phase 3 | Not yet recruiting | Takeda | 40 | 2026-11-01 | 2026-10-20 |
| A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis COL-5671-PRO, Placebo - Plaque Psoriasis | Phase 2 | Not yet recruiting | Coultreon Biopharma | 100 | 2026-10-31 | 2026-11-03 |
| Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. Crisaborole 2% topical ointment, tacrolimus ointment 0.1% - Psoriasis, Psoriasis Genital | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-10-25 | 2026-10-27 |
| A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 132 | 2026-10-20 | 2026-10-27 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-14 | 2026-10-13 |
| A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults HCXT-2001 Tablets, Placebo, HCXT-2001 Tablets(A) - Psoriasis | Phase 1 | Not yet recruiting | Shanghai Peptidstar Therapeutics Limited | 40 | 2026-10-14 | 2026-10-13 |
| Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis Raster-Scan Optoacoustic Mesoscopy, Multispectral Optoacoustic Tomography, Skin Biopsy and Skin Sample Collection - Psoriasis (PsO), Psoriasis Arthritis | Not applicable | Not yet recruiting | University of Erlangen-Nürnberg Medical School | 192 | 2026-10-07 | 2026-10-21 |
| Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA) Narrowband UVB Phototherapy, Ceramol PSOR Cream, Comparator Emollient Cream - Psoriasis, Psoriasis; Plaque | Not applicable | Not yet recruiting | Unifarco SpA | 128 | 2026-10-01 | 2026-09-30 |
| Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients Meibomian Gland Dysfunction, Dry Eye Syndromes | Not yet recruiting | Assiut University | 150 | 2026-10-01 | 2026-09-09 | |
| Assessing Psoriasis Treatment Outcomes Artificial intelligence, Human, Standard of Care - Psoriasis | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 15 | 2026-10-01 | 2026-08-04 |
| A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis 5% GM-XANTHO [GM-XAN003], Placebo - Psoriasis | Phase 2 | Not yet recruiting | Xantho Biotechnology Co., LTD | 65 | 2026-10-01 | 2026-08-07 |
Showing 20 of 1933. Sign in to see all of them.
Arthritis, Psoriatic (593) · Arthritis, Rheumatoid (204) · Spondylitis, Ankylosing (111) · Dermatitis, Atopic (76) · Arthritis (64) · Crohn Disease (61) · Skin Diseases (61) · Colitis, Ulcerative (46) · Spondylarthritis (40) · Inflammation (35) · Pruritus (33) · Axial Spondyloarthritis (31) · Eczema (31) · Obesity (31)
Skin and Connective Tissue Diseases (1930) · Skin Diseases, Papulosquamous (1925) · Skin Diseases (1872) · Musculoskeletal Diseases (635) · Joint Diseases (622) · Bone Diseases (609) · Spinal Diseases (605) · Spondylitis (598) · Spondylarthropathies (585) · Arthritis (567) · Spondylarthritis (565) · Immune System Diseases (331) · Connective Tissue Diseases (222) · Rheumatic Diseases (207)
Adalimumab (93) · secukinumab (93) · Etanercept (86) · Methotrexate (61) · Ustekinumab (59) · apremilast (59) · guselkumab (49) · risankizumab (43) · Infliximab (41) · deucravacitinib (33) · bimekizumab (31) · calcipotriene (27) · ixekizumab (27) · tofacitinib (27) · brodalumab (25)
Novartis Pharmaceuticals (69) · AbbVie (65) · Amgen (62) · Pfizer (53) · Bristol-Myers Squibb (39) · Janssen Research & Development, LLC (34) · Eli Lilly and Company (30) · AbbVie (prior sponsor, Abbott) (23) · UCB Biopharma SRL (23) · Bausch Health Americas, Inc. (21) · Boehringer Ingelheim (21) · Merck Sharp & Dohme LLC (21) · Abbott (20) · Cairo University (19) · University of Pennsylvania (16)
United States (696) · Germany (296) · Canada (277) · France (198) · Poland (190) · United Kingdom (184) · Spain (175) · China (161) · Italy (132) · Hungary (126) · Belgium (119) · Czechia (115) · Australia (114) · Japan (100) · Russia (98)
PMID 37906417, PMID 32816215, PMID 37316690, PMID 35544084, PMID 30739254, PMID 31667790, PMID 38446397, PMID 31054118, PMID 32207067, PMID 35305260, PMID 37400681, PMID 38488975, PMID 39120849, PMID 39578348, PMID 40194794, PMID 41060492, PMID 41580158, PMID 41800601, PMID 41807031, PMID 25913550, PMID 27573260, PMID 27576559, PMID 34110605, PMID 34795065, PMID 34921669, PMID 35279805, PMID 35393269, PMID 36178584, PMID 36642439, PMID 36751950, PMID 37076998, PMID 37341961, PMID 37950894, PMID 39073712, PMID 39120848, PMID 40241921, PMID 40286813, PMID 40886218, PMID 41359217, PMID 42825996, PMID 26547918, PMID 26953848, PMID 27299809, PMID 29380251, PMID 30018799, PMID 31077258, PMID 31112005, PMID 31203228, PMID 31909868, PMID 31964419
2016 (36), 2018 (26), 2023 (25), 2017 (23), 2014 (20), 2015 (16), 2019 (15), 2025 (8), 2005 (7), 2009 (7), 2008 (2), K08CA237619 (1), K23AR080043 (1), K23HL152013 (1), P20GM130414 (1)